Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous drug delivery
Biotech
Viridian’s Tepezza rival racks up another ph. 3 win
Viridian is preparing to file for FDA approval next year and challenge Amgen for a blockbuster market.
Nick Paul Taylor
May 5, 2026 8:00am
Fierce Pharma
Halozyme catches M&A wave to snap up Surf Bio
Jan 28, 2026 2:06pm
Fierce Pharma
Halozyme CEO targets new deals as IRA uncertainty subsides
Oct 14, 2025 9:40am
Fierce Pharma
Halozyme buys Elektrofi for up to $900M
Oct 1, 2025 2:36pm
Lundbeck ends subcutaneous migraine cohort after futility review
Apr 1, 2025 5:00am
Glenmark bags subcutaneous checkpoint inhibitor rights
Jan 25, 2024 9:30am